Risperdal Lawsuit Jury Delivers Mixed Verdict, as Second Gynecomastia Bellwether Trial Concludes in Pennsylvania Mass Tort Program

Share Article

Bernstein Liebhard LLP is representing numerous Risperdal plaintiffs in the Pennsylvania litigation, all of whom allegedly experienced excessive male breast growth due to their use of the antipsychotic medication.

Free Case Review
It should be noted that this litigation is far from over, as other Risperdal claims involving male breast growth are scheduled to go to trial in this proceeding in the coming months.

The second bellwether trial of a Risperdal lawsuit (http://www.risperdallawsuit2014.com/) involving allegations that the drug causes gynecomastia (male breast growth) has concluded in a mass tort program underway in Pennsylvania’s Philadelphia Court of Common Pleas. According to court documents, the jury hearing the case rendered a mixed verdict on March 20th, agreeing with the lawsuit’s assertion that Johnson & Johnson and its Janssen Pharmaceuticals division failed to warn of Risperdal’s association with male breast growth. However, the jury elected not to award any damages to the plaintiff, after concluding that there was no direct connection between the drug and his condition. (Case No. 130301803)

“While it is disappointing that the jury chose not to award damages in this case, this verdict is still very significant because it marks the second time in a month that a Pennsylvania jury has found that Risperdal’s manufacturers failed to warn of its potential to cause gynecomastia. It should be noted that this litigation is far from over, as other Risperdal claims involving male breast growth are scheduled to go to trial in this proceeding in the coming months,” said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently representing numerous Risperdal gynecomastia plaintiffs in the Pennsylvania litigation, and continues to provide legal consultations to men and boys who allegedly developed this condition due to their use of the medication.

Risperdal Litigation
Court documents indicate that nearly 1,300 Risperdal lawsuits are currently pending in the Pennsylvania mass tort program, all of which accuse Johnson & Johnson and Janssen of concealing the risks associated with the drug, and of failing to warn doctors and patients about the complications that could occur with its use. According to Bernstein Liebhard LLP, bellwether trials mark important milestones in these types of proceedings, as their outcomes could provide valuable insight into possible jury rulings in similar trials involving Risperdal and gynecomastia. (In Re: Risperdal Litigation, Case Number 100300296)

According to court records, the just-concluded trial involved a claim filed on behalf of a man who was prescribed Risperdal off-label as a child to treat oppositional defiant disorder. Like other gynecomastia lawsuits pending in the proceeding, the complaint alleged that Johnson & Johnson and Janssen had concealed data linking Risperdal to unusually high levels of a hormone called prolactin, which is related to female breast growth and the development of gynecomastia in men and boys. The complaint also accused the companies of improperly promoting the drug for off-label use in children.

Court filings show that the proceeding’s first bellwether trial of a Risperdal gynecomastia lawsuit concluded on February 24th, with the jury awarding $2.5 million to a man who was prescribed the medication off-label as a boy to treat autism. According to the complaint, the plaintiff developed size 44 DD breasts as a result of his treatment with Risperdal. (Case No. A-196444)

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website